NYSE$UHS

Universal Health Services Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

UHS's net income attributable to UHS was $261.8 million, or $3.82 per diluted share, and net revenues increased by 10.8% to $3.844 billion.

Universal Health Services, Inc. reported a strong first quarter in 2024, with net income attributable to UHS reaching $261.8 million, or $3.82 per diluted share, compared to $163.1 million, or $2.28 per diluted share, in the first quarter of 2023. Net revenues also saw a substantial increase of 10.8% to $3.844 billion.

  • Net income attributable to UHS was $261.8 million, or $3.82 per diluted share.
  • Net revenues increased by 10.8% to $3.844 billion.
  • Adjusted net income attributable to UHS was $253.1 million, or $3.70 per diluted share.
  • Net cash provided by operating activities was $396 million.

Headline financials

Total Revenue

$3.84B

Previous: $3.47B+10.8%
EPS

$3.82

Previous: $2.34+63.2%
Avg Licensed Beds

6.7K

Previous: 6.8K-2.1%
Avg Available Beds

6.5K

Previous: 6.6K-2.1%
Patient Days

415.3K

Previous: 404.3K+2.7%
Avg Daily Census

4.6K

Previous: 4.5K+1.6%
Occupancy Licensed Beds

68.6%

Previous: 66.1%+3.8%
Occupancy Available Beds

70.4%

Previous: 67.8%+3.8%
Admissions

83.6K

Previous: 80.1K+4.3%
Length of Stay

5

Previous: 5+0.0%
BH Avg Licensed Beds

24.4K

Previous: 24.2K+0.6%
BH Avg Available Beds

24.3K

Previous: 24.1K+0.6%
BH Patient Days

1.6M

Previous: 1.6M+2.3%
BH Avg Daily Census

17.7K

Previous: 17.5K+1.2%
BH Occupancy Licensed

72.5%

Previous: 72.1%+0.6%
BH Occupancy Available

72.8%

Previous: 72.4%+0.6%
BH Admissions

119.9K

Previous: 120.6K-0.5%
BH Length of Stay

13.4

Previous: 13+3.1%
Capital Expenditures

-$209M

Previous: -$169M-23.6%
Free Cash Flow

$53.3M

Previous: -$5.64M+1045.4%
Net Income

$262M

Previous: $163M+60.5%
Operating Income

$389M

Previous: $279M+39.5%
Cash & Equivalents

$112M

Previous: $110M+1.9%
Total Assets

$14B

Previous: $13.6B+3.6%
Stock-Based Comp

$19.6M

Previous: $21M-6.4%

Revenue & EPS history

UHS · Revenue · Quarterly

$3.84B

Q1 2024+10.8%vs Q1 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

UHS · $3.56B total across 2 segments · Q3 2023

  • Acute Care Services
    $2.02B+5.1%
  • Behavioral Health Services
    $1.54B+7.5%

Forward guidance

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors, and Item 7-Forward-Looking Statements and Risk Factors, in our Form 10-K for the year ended December 31, 2023), may cause the results to differ materially from those anticipated in the forward-looking statements.

Tailwinds

  • UHS has built an impressive record of achievement and performance.
  • UHS ranked #311 on the Fortune 500; and #434 on Forbes’ list of America’s Largest Public Companies
  • UHS was again recognized as one of the World’s Most Admired Companies by Fortune.
  • Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.
  • Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headwinds

  • A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs.
  • The increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms.
  • The outcome of known and unknown litigation, liabilities and other claims asserted against us and/or our subsidiaries, including, but not limited to, the March 28, 2024, jury award (of compensatory damages of $60 million and punitive damages of $475 million) against The Pavilion Behavioral Health System
  • Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions.
  • Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.3%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+0.7%

Avg return

30 days after

49%

34 / 69 earnings

Positive

+17.5%

Q3 2022

Best reaction

-13.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.5%-7.0%-16.4%
Q4 2025-5.5%-1.0%-9.9%
Q3 2025+2.5%+1.4%+14.1%
Q2 2025-0.2%+3.3%+7.3%
Q1 2025-0.6%+3.4%+10.5%
Q4 2024+3.3%-3.8%+3.4%
Q3 2024-13.4%-12.1%-15.5%
Q2 2024+10.6%+17.3%+25.8%
Q1 2024+0.1%+2.6%+6.9%
Q4 2023-1.6%+4.1%+11.0%
Q3 2023-0.2%-0.6%+11.4%
Q2 2023-4.6%-6.5%-12.3%
Q1 2023+1.5%+6.9%-9.3%
Q4 2022-9.1%-13.5%-15.5%
Q3 2022+17.5%+25.8%+39.3%
Q2 2022-1.5%+1.3%-5.7%
Q1 2022-5.7%-7.8%-8.1%
Q4 2021+8.6%+8.7%+11.1%
Q3 2021-7.0%-8.5%-5.0%
Q2 2021+4.2%+5.1%+1.6%
Q1 2021+0.3%+2.0%+10.1%
Q4 2020-9.1%-6.2%-2.0%
Q3 2020+3.0%+11.1%+24.2%
Q2 2020+0.9%+1.7%+0.2%
Q1 2020+3.7%-2.5%+8.6%
Q4 2019-5.3%-2.7%-34.3%
Q3 2019-4.6%-4.0%-3.6%
Q2 2019+10.9%+11.6%+4.7%
Q1 2019-0.8%-2.6%-5.5%
Q4 2018+3.9%+2.7%+0.1%
Q3 2018-5.3%-1.0%+8.0%
Q2 2018+9.3%+9.3%+12.0%
Q1 2018-4.6%-5.2%-3.2%
Q4 2017-1.3%+5.3%+0.7%
Q3 2017-6.9%-8.3%-9.9%
Q2 2017-9.2%-10.3%-12.6%
Q1 2017-2.0%-0.1%-3.0%
Q4 2016-0.9%-0.8%-0.8%
Q3 2016+0.6%-0.7%+1.3%
Q2 2016-4.4%-5.2%-12.1%
Q1 2016+2.1%
Q4 2015+2.4%
Q3 2015+2.4%
Q2 2015+2.1%
Q1 2015-0.7%
Q4 2014+3.8%
Q3 2014-1.0%
Q2 2014+6.8%
Q1 2014+8.3%
Q4 2013-2.6%
Q3 2013+2.6%
Q2 2013+3.3%
Q1 2013+3.3%
Q4 2012-0.0%
Q3 2012-3.2%
Q2 2012+4.8%
Q1 2012-1.7%
Q2 2011+2.0%
Q4 2011+2.0%
Q3 2011+3.8%
Q1 2010+3.8%
Q4 2010+3.8%
Q1 2011+3.8%
Q2 2010+5.0%
Q3 2009+0.0%
Q3 2010+0.0%
Q4 2009-0.3%
Q2 2009-0.3%
Q4 2008-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro